Abstracts tagged "Cell Death"

Abstract Number: 0630 • ACR Convergence 2022
Ferroptosis of CD163+ Tissue Infiltrating Macrophages in Lupus Nephritis
Qi Cheng, Huaxiang Wu and Yan Du, The Second Affiliated Hospital Of Zhejiang University School Of Medicine, Hangzhou, China
Background/Purpose: Lupus nephritis (LN) is one of the most common complications of systemic lupus erythematosus (SLE), with high morbidity and mortality. Despite a better understanding…
Abstract Number: 0653 • ACR Convergence 2022
JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro
Hiroshi Kajiyama¹, Yoshimi Aizaki², Hiroaki Yazawa³, Kazuhiro Yokota³, Yasuto Araki², Yuji Akiyama² and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Yokohama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Hydroxychloroquine (HCQ) is an anti-malarial medicine and an immunomodulator to treat autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clinical…
Abstract Number: 0694 • ACR Convergence 2021
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis
Mari Kamiya¹, Fumitaka Mizoguchi¹, Hirokazu Sasaki², Natsuka Umezawa¹ and Shinsuke Yasuda³, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ³Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: While glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM), GC-induced myopathy is inevitable, which deteriorates muscle weakness. Therefore, novel therapeutic strategy…
Abstract Number: 0975 • ACR Convergence 2020
Gasdermin D Modulates Murine Lupus and Its Associated Organ Damage
Xinghao Wang¹, Luz Blanco², Carmelo Carmona-Rivera³, Shuichiro Nakabo³, Hege Pedersen⁴, Zu-Xi Yu⁵ and Mariana Kaplan³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Canton, MI, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, ⁵National Heart, Lung, and Blood Institute Pathology Core, Bethesda
Background/Purpose: Gasdermin D (GSDMD) is the key executioner of the inflammatory cell death mechanism pyroptosis. Recent reports have also implicated GSDMD in other mechanisms of…
Abstract Number: 1077 • ACR Convergence 2020
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Fiber Death, and Ameliorates Muscle Weakness in Experimental Polymyositis
Mari Kamiya¹, Seon Uk Kim², Jeong Yeon Kim³, Shinsuke Yasuda⁴, Eun Young Lee⁵ and Fumitaka Mizoguchi¹, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Jongno-gu, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, ⁴Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM). However, the treatment with GC causes GC-induced myopathy, which further deteriorates the muscle…
Abstract Number: 1532 • ACR Convergence 2020
The Non-psychotropic Phytocannabinoids Cannabigerol and Tetrahydrocannabinolic Acid Inhibit Rheumatoid Arthritis Synovial Fibroblast Function by Targeting the Wasabi Receptor TRPA1
Torsten Lowin¹, Matthias Schneider² and Georg Pongratz³, ¹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Düsseldorf, Germany, ²Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany, ³Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, D�sseldorf, Germany
Background/Purpose: While medical cannabis is available for german patients since 2017, its use to alleviate symptoms of rheumatic diseases is not recommended due to a…
Abstract Number: 1950 • ACR Convergence 2020
Elevated Serum Gasdermin D N-terminal Implicates Macrophage Pyroptosis in Adult-onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis
Hideto Nagai¹, Yohei Kirino², Hiroto Nakano³, Yosuke Kunishita¹ and Michael Ombrello⁴, ¹Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³NIAMS, NIH, Bethesda, ⁴Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD
Background/Purpose: Elevation of serum IL-18 in adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA) suggests involvement of one or more inflammasome in these…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].